Stock listing
NASDAQ:ANTX AN2 Therapeutics, Inc. Stock
Home listing (NASDAQ) of AN2 Therapeutics, Inc.
Follow AN2 Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ANTX
$5.08 USD +0.13 (+2.6%)
Close on Nov 20, 2026
- Day range
- $4.99 – $5.49 USDNov 20, 2026
- Volume
- 332,710 sharesNov 20, 2026
- Market cap
- $192.8M USDAt the close on Nov 20, 2026 · price × 37.94M shares outstanding
- 52-week range
- $1.00 – $7.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.33M USDMedian day 240,355 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ANTX · Home | $5.08 USD | +0.13 (+2.6%) | 332,710 | $5.13 | $5.49 | $4.99 | $4.95 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.08 | +0.13 | +2.6% | $5.13 | $5.49 | $4.99 | 332,710 | |
| $4.95 | +0.72 | +17.0% | $4.40 | $5.32 | $4.23 | 967,421 | |
| $4.23 | -0.24 | -5.4% | $4.50 | $4.60 | $3.915 | 285,651 | |
| $4.47 | -0.08 | -1.8% | $4.51 | $4.70 | $4.365 | 246,860 | |
| $4.55 | +0.11 | +2.5% | $4.42 | $4.58 | $4.25 | 205,686 | |
| $4.44 | -0.02 | -0.4% | $4.48 | $4.75 | $4.34 | 186,344 | |
| $4.46 | +0.13 | +3.0% | $4.40 | $4.747 | $4.277 | 197,630 | |
| $4.33 | +0.33 | +8.3% | $3.99 | $4.505 | $3.93 | 271,603 | |
| $4.00 | 0.00 | 0.0% | $4.06 | $4.13 | $3.97 | 496,679 | |
| $4.00 | +0.045 | +1.1% | $3.99 | $4.11 | $3.90 | 240,355 | |
| $3.955 | -0.295 | -6.9% | $4.22 | $4.255 | $3.82 | 152,967 | |
| $4.25 | +0.07 | +1.7% | $4.22 | $4.31 | $4.10 | 131,826 | |
| $4.18 | -0.17 | -3.9% | $4.38 | $4.55 | $4.10 | 160,400 | |
| $4.35 | -0.18 | -4.0% | $4.54 | $4.64 | $4.241 | 299,604 | |
| $4.53 | -0.16 | -3.4% | $4.66 | $4.76 | $4.31 | 284,722 | |
| $4.69 | +0.17 | +3.8% | $4.57 | $4.90 | $4.53 | 555,792 | |
| $4.52 | +0.66 | +17.1% | $3.86 | $4.60 | $3.85 | 545,417 | |
| $3.86 | +0.23 | +6.3% | $3.61 | $3.89 | $3.54 | 239,623 | |
| $3.63 | +0.08 | +2.3% | $3.55 | $3.70 | $3.50 | 196,183 | |
| $3.55 | -0.09 | -2.5% | $3.61 | $3.66 | $3.47 | 124,439 | |
| $3.64 | +0.04 | +1.1% | $3.57 | $3.72 | $3.521 | 95,191 | |
| $3.60 | +0.04 | +1.1% | $3.58 | $3.78 | $3.57 | 177,367 | |
| $3.56 | +0.19 | +5.6% | $3.38 | $3.59 | $3.36 | 129,744 | |
| $3.37 | -0.01 | -0.3% | $3.39 | $3.46 | $3.21 | 330,870 | |
| $3.38 | -0.22 | -6.1% | $3.60 | $3.62 | $3.30 | 281,730 | |
| $3.60 | +0.06 | +1.7% | $3.50 | $3.69 | $3.50 | 295,943 | |
| $3.54 | -0.06 | -1.7% | $3.55 | $3.73 | $3.33 | 431,025 | |
| $3.60 | -0.70 | -16.3% | $4.30 | $4.32 | $3.59 | 515,050 | |
| $4.30 | -0.10 | -2.3% | $4.41 | $4.41 | $4.24 | 298,465 | |
| $4.40 | -0.28 | -6.0% | $4.65 | $4.67 | $4.26 | 442,134 | |
| $4.68 | -0.17 | -3.5% | $4.77 | $4.86 | $4.43 | 427,826 | |
| $4.85 | -0.22 | -4.3% | $5.02 | $5.06 | $4.695 | 365,253 | |
| $5.07 | -0.54 | -9.6% | $5.39 | $5.60 | $5.005 | 318,215 | |
| $5.61 | -0.10 | -1.8% | $5.69 | $5.86 | $5.50 | 299,949 | |
| $5.71 | +0.09 | +1.6% | $5.64 | $5.99 | $5.51 | 451,333 | |
| $5.62 | +0.30 | +5.6% | $5.29 | $5.73 | $5.155 | 509,439 | |
| $5.32 | +0.23 | +4.5% | $5.07 | $5.35 | $5.00 | 199,204 | |
| $5.09 | +0.08 | +1.6% | $4.99 | $5.20 | $4.76 | 178,839 | |
| $5.01 | +0.13 | +2.7% | $4.89 | $5.17 | $4.67 | 318,456 | |
| $4.88 | -0.01 | -0.2% | $4.91 | $4.95 | $4.71 | 155,127 | |
| $4.89 | +0.06 | +1.2% | $4.77 | $5.06 | $4.72 | 258,937 | |
| $4.83 | 0.00 | 0.0% | $4.86 | $4.95 | $4.67 | 306,158 | |
| $4.83 | -0.13 | -2.6% | $5.00 | $5.05 | $4.70 | 191,680 | |
| $4.96 | -0.09 | -1.8% | $5.06 | $5.25 | $4.92 | 305,221 | |
| $5.05 | +0.15 | +3.1% | $4.89 | $5.15 | $4.80 | 670,954 | |
| $4.90 | -0.44 | -8.2% | $5.39 | $5.47 | $4.88 | 204,494 | |
| $5.34 | -0.02 | -0.4% | $5.38 | $5.44 | $5.295 | 146,046 | |
| $5.36 | -0.10 | -1.8% | $5.43 | $5.50 | $5.20 | 156,797 | |
| $5.46 | +0.05 | +0.9% | $5.43 | $5.645 | $5.34 | 221,486 | |
| $5.41 | -0.28 | -4.9% | $5.70 | $5.78 | $5.40 | 103,538 | |
| $5.69 | -0.04 | -0.7% | $5.56 | $5.88 | $5.54 | 222,312 | |
| $5.73 | -0.25 | -4.2% | $5.98 | $6.125 | $5.605 | 175,804 | |
| $5.98 | +0.09 | +1.5% | $6.00 | $6.06 | $5.76 | 335,287 | |
| $5.89 | -0.06 | -1.0% | $5.97 | $6.06 | $5.85 | 77,182 | |
| $5.95 | 0.00 | 0.0% | $6.05 | $6.20 | $5.79 | 199,660 | |
| $5.95 | +0.47 | +8.6% | $5.46 | $6.00 | $5.46 | 353,561 | |
| $5.48 | -0.07 | -1.3% | $5.53 | $5.67 | $5.40 | 215,423 | |
| $5.55 | -0.03 | -0.5% | $5.58 | $5.645 | $5.40 | 124,021 | |
| $5.58 | -0.16 | -2.8% | $5.67 | $5.78 | $5.40 | 240,866 | |
| $5.74 | +0.21 | +3.8% | $5.46 | $5.79 | $5.46 | 204,041 | |
| $5.53 | -0.13 | -2.3% | $5.66 | $5.85 | $5.50 | 287,524 | |
| $5.66 | +0.03 | +0.5% | $5.67 | $5.80 | $5.60 | 217,706 | |
| $5.63 | -0.18 | -3.1% | $5.82 | $5.82 | $5.59 | 171,420 | |
| $5.81 | +0.02 | +0.3% | $5.84 | $5.89 | $5.50 | 225,449 | |
| $5.79 | -0.17 | -2.9% | $5.98 | $6.13 | $5.72 | 195,335 |
- Ticker
- NASDAQ:ANTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 50 slides
Latest news
AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Nov 9, 2026
Closed $4.00 (0.0%) on Nov 9, 2026
AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
Nov 4, 2026
Closed $3.96 (-6.9%) on Nov 5, 2026
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Nov 4, 2026
Closed $4.25 (+1.7%) on Nov 4, 2026
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
Nov 2, 2026
Closed $4.35 (-4.0%) on Nov 2, 2026
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Oct 23, 2026
Closed $3.63 (+2.3%) on Oct 26, 2026
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
Oct 21, 2026
Closed $3.60 (+1.1%) on Oct 21, 2026
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Oct 20, 2026
Closed $3.60 (+1.1%) on Oct 21, 2026
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Sep 28, 2026
Closed $5.01 (+2.7%) on Sep 28, 2026
AN2 Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 62 in all · newest Nov 20, 2026 · oldest 2022
- Decks
- 3 decks · latest September 2026
Where AN2 Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ANTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ANTX | BOATS | United States | USD |
Valuation
Price/book 2.5× against a median of 2.7×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $128.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.54
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. · NASDAQ:ANTX | US$192.8M | US$128.4M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.54 |
| Bright Minds Biosciences Inc. · CSE:DRUG | US$199.5M | −US$15.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.32 |
| Newron Pharmaceuticals S.p.A. · SIX:NWRN | US$199.5M | US$206.2M | n/a | 9.8× | n/a | n/a | −69.2% | n/a | n/a |
| NervGen Pharma Corp. · NASDAQ:NGEN | US$198.4M | US$137.8M | n/a | n/a | n/a | 16.4× | n/a | 0.0× | 1.46 |
| BioAge Labs, Inc. · NASDAQ:BIOA | US$196.4M | −US$87.20M | n/a | −10.1× | n/a | 0.6× | n/a | 0.0× | 2.06 |
| Lineage Cell Therapeutics, Inc. · AMEX:LCTX | US$195.3M | US$152.1M | 111× | 14.0× | n/a | 2.9× | 16.2% | 0.0× | 1.33 |
| AC Immune SA · NASDAQ:ACIU | US$193.9M | US$110.5M | n/a | 4.7× | n/a | 6.0× | −181.9% | 0.1× | 1.56 |
| SillaJen, Inc. · KRX:215600 | US$193.5M | US$141.7M | n/a | 17.6× | n/a | 2.6× | −223.8% | 0.0× | n/a |
| Cartesian Therapeutics, Inc. · NASDAQ:RNAC | US$187.3M | US$114.5M | n/a | 112× | n/a | n/a | n/a | n/a | 1.23 |
| Artiva Biotherapeutics, Inc. · NASDAQ:ARTV | US$186.9M | −US$123.1M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.34 |
| Inventage Lab, Inc. · KRX:389470 | US$185.9M | US$113.3M | n/a | 61.3× | n/a | 2.8× | −127.0% | 0.2× | n/a |
| Median of the others | US$194.6M | US$113.9M | 111× | 14.0× | 2.7× | −127.0% | 0.0× | 1.34 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.81 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Eric Easom | Co-founder, President, CEO, and Chair |
| Maggie FitzPatrick | Fitzpatrick & Co, Founder & CEO, Lead Independent Director |
| Lucy O. Day | Chief Financial Officer |
| Lynn Marks | Senior Vice President (Retired), GlaxoSmithKline |
| Cameron Trenor | Chief Medical Officer |
| Joseph S. Zakrzewski | Co-Founder |
| Rob Readnour | Managing Director, Mountain Group Partners, Director |
Board
| Director | Role |
|---|---|
| Eric Easom | Co-founder, President, CEO, and Chair |
| Joseph S. Zakrzewski | Co-Founder |
| Kabeer Aziz | Principal, Adjuvant Capital |
| Lynn Marks | Senior Vice President (Retired), GlaxoSmithKline |
| Maggie FitzPatrick | Fitzpatrick & Co, Founder & CEO, Lead Independent Director |
| Melvin Spigelman | GATB |
| Patricia Martin | Director |
| Stephanie Wong | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | 0.0% |
| Q2 2026 | Aug 11, 2026 · After close | +7.0% |
| Q1 2026 | May 11, 2026 · After close | −9.5% |
| Q4 2025 | Mar 18, 2026 | −21.8% |
| Q3 2025 | Nov 12, 2025 · After close | −4.2% |
| Q2 2025 | Aug 14, 2025 · After close | +1.4% |
| Q1 2025 | May 13, 2025 · After close | +0.8% |
| Q4 2024 | Mar 25, 2025 | +0.7% |
| Q3 2024 | Nov 13, 2024 · After close | −1.0% |
| Q2 2024 | Aug 13, 2024 · After close | −3.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | −1.7% |
| Q4 2023 | Mar 28, 2024 · After close | +15.7% |
| Q3 2023 | Nov 9, 2023 · After close | −7.1% |
| Q2 2023 | Aug 10, 2023 · After close | +0.4% |
| Q1 2023 | May 11, 2023 · After close | +0.6% |
| Q4 2022 | Mar 29, 2023 · After close | −1.9% |
| Q3 2022 | Nov 9, 2022 · After close | −7.4% |
| Q2 2022 | Aug 11, 2022 · After close | +64.7% |
| Q1 2022 | May 10, 2022 · After close | +6.8% |
| Q4 2021 | Mar 28, 2022 · After close | −2.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 50 slides | September 2026 |
| Corporate Update (March 2026) | Corporate update | 17 slides | Mar 4, 2026 |
| Investor Presentation (June 2025) | Investor deck | 40 slides | Jun 11, 2025 |
IPO
Priced at US$15.00 a share on Mar 24, 2022.
- Price
- US$15.00 a share
- Shares offered
- 4,600,000 shares of common stock
- Offering size
- US$69 million
- Underwriters' option
- Up to 690,000 more shares
- Underwriters
- Cowen, SVB Leerink, Evercore ISI, Oppenheimer & Co. · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 24, 2021 |
| Filed publicly | Mar 4, 2022 |
| Amended once | Mar 21, 2022 |
| Shares registered with an exchange | Mar 22, 2022 |
| Declared effective by the SEC | Mar 24, 2022 |
| Final prospectus, with the price | Mar 28, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 28, 2022 |
| EFFECT · Notice that a registration is effective | Mar 24, 2022 |
| S-1MEF · Registration of more shares for the same offering | Mar 24, 2022 |
| CERT · Exchange's certificate of listing | Mar 24, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 22, 2022 |
| CORRESP · Letter to the SEC | Mar 22, 2022 |
| CORRESP · Letter to the SEC | Mar 22, 2022 |
| S-1/A · Registration statement, amended | Mar 21, 2022 |
| S-1 · Registration statement | Mar 4, 2022 |
| DRSLTR · Letter to the SEC with a draft | Jan 19, 2022 |
All 16 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | Jan 19, 2022 |
| UPLOAD · Letter from the SEC | Dec 3, 2021 |
| DRS/A · Draft registration statement, amended | Nov 19, 2021 |
| DRSLTR · Letter to the SEC with a draft | Nov 18, 2021 |
| UPLOAD · Letter from the SEC | Oct 22, 2021 |
| DRS · Draft registration statement | Sep 24, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 28, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 77.0K | ||||||
| Gross profit | -77.0K | ||||||
| Research and development | 24.8M | 40.5M | 54.9M | 28.5M | 16.2M | 6.02M | 29.3M |
| Selling, general and administrative | 13.3M | 14.1M | 14.8M | 12.8M | 4.67M | 1.26M | 1.73M |
| Operating income | -38.1M | -56.8M | -69.6M | -42.3M | -21.6M | -7.28M | -31.1M |
| Depreciation and amortization | 54.6M | 69.6M | 692.0K | 100.0K | 7.28M | 31.1M | |
| EBITDA | -2.23M | 0 | -41.6M | -21.5M | 0 | 0 | |
| Interest expense | 514.0K | 69.0K | 3.00K | 0 | |||
| Income before tax | -35.2M | -51.3M | -64.7M | -41.0M | -21.5M | -13.6M | -33.8M |
| Income tax | 0 | 0 | 0 | 0 | 0 | -3.00K | -31.1K |
| Net income | -35.2M | -51.3M | -64.7M | -41.0M | -21.5M | -13.6M | -33.8M |
| Earnings per share, basic | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 | -0.73 | -1.80 |
| Earnings per share, diluted | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 19.9M | 21.4M | 15.6M | 27.2M | 12.1M | 4.07M | 5.60M |
| Short-term investments | 38.1M | 62.3M | 91.6M | 68.8M | 46.5M | 0 | |
| Receivables | 900.0K | 300.0K | 1.40M | ||||
| Current assets | 59.9M | 86.3M | 110.5M | 98.6M | 60.1M | 4.23M | 5.70M |
| Total assets | 62.0M | 92.1M | 138.7M | 102.6M | 65.3M | 4.23M | 5.70M |
| Accounts payable | 3.02M | 3.32M | 2.68M | 2.12M | 1.06M | 132.0K | 51.0K |
| Current liabilities | 8.72M | 10.2M | 14.0M | 7.19M | 3.40M | 1.46M | 159.0K |
| Total debt | 53.0K | 728.0K | |||||
| Total liabilities | 8.89M | 10.2M | 14.0M | 7.19M | 3.41M | 1.48M | 887.0K |
| Shareholders' equity | 53.1M | 81.8M | 124.7M | 95.4M | -47.4M | 2.75M | 4.81M |
| Shares outstanding | 27.4M | 29.9M | 29.7M | 19.4M | 2.73M | 18.7M | 18.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -29.8M | -49.3M | -53.3M | -33.5M | -20.5M | -5.36M | -2.49M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -29.8M | -49.3M | -53.3M | -33.5M | -20.5M | -5.36M | -2.49M |
| Cash from investing | 28.3M | 54.6M | -43.3M | -21.8M | -50.0M | -50.0M | -50.0M |
| Cash from financing | 113.0K | 372.0K | 85.0M | 70.4M | 78.5M | 3.84M | 8.08M |
| Dividends paid | -1.82M | ||||||
| Share buybacks | -11.0K | ||||||
| Change in cash | -1.41M | 5.70M | -11.6M | 15.1M | 8.03M | -1.53M | 5.60M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Sep 14, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 21, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 20, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Apr 20, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 16, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Apr 9, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 9, 2026 | Current report | SEC |
| D | Mar 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 9, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Financing | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 18, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 8-K · Current report | May 27, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 10, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 28, 2024 | Big-stake notice | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Aug 19, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 19, 2024 | Material contract | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jul 3, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 24, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | May 14, 2024 | Annual report | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
This page holds 200 of 390 filings. Open Filings
Cap table
Built by 6ix from AN2 Therapeutics, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 37,943,650
- Fully diluted
- 37,943,650
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 37,943,650 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 37,943,650 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Melvin Spigelman Other companies: Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Aug 15, 2018 · Past); The Medicines Company (Director · May 25, 2006 – May 25, 2018 · Past) | GATB · Since at least Mar 24, 2022 |
| Margaret M FitzPatrick Other companies: Vistagen Therapeutics, Inc. (Director · Since at least Jul 21, 2021) | Director · Since at least May 5, 2022 |
| Michael Adrian Nazak Other companies: Aridis Pharmaceuticals Inc. (Chief Financial Officer · Feb 18, 2021 – Feb 18, 2021 · Past) | Chief Accounting Officer · Mar 24, 2022 – Feb 15, 2023 · Past |
| Patricia Martin Other companies: Cypherpunk Technologies Inc. (Director · Since at least Jan 17, 2023) | Director · Since at least May 12, 2022 |
| Cameron C Trenor III | Chief Medical Officer · Since at least Aug 24, 2026 |
| Cameron Trenor | Chief Medical Officer · Since at least Aug 24, 2026 |
| Eric Easom | Co-founder, President, CEO, and Chair · Since at least Oct 20, 2026 |
| Gilbert Lynn Marks | Director · Since at least Mar 24, 2022 |
| Joseph S. Zakrzewski | Director · Since at least Aug 14, 2026 |
| Joshua M Eizen | See Remarks · Since at least Jul 8, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Kabeer Aziz | Director · Since at least Mar 24, 2022 |
| Lucy O. Day | Chief Financial Officer · Since at least Mar 24, 2022 |
| Lynn Marks | Senior Vice President (Retired), GlaxoSmithKline · Since at least Nov 5, 2026 |
| Maggie FitzPatrick | Fitzpatrick & Co, Founder & CEO, Lead Independent Director · Since at least Sep 2, 2026 |
| Paul Eckburg | Chief Medical Officer · Mar 24, 2022 – Mar 15, 2024 · Past |
| Robin Shane Readnour | Director · Since at least Mar 24, 2022 |
| Rob Readnour | Managing Director, Mountain Group Partners, Director · Since at least Nov 4, 2026 |
| Sanjay Chanda | Chief Development Officer · Since at least Mar 24, 2022 |
| Sarah Joanne Williams | Principal Accounting Officer · Since at least Jan 26, 2026 |
| Stephanie Wong | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about AN2 Therapeutics, Inc.